颗粒物2.5和阿尔茨海默病之间的因果关系:孟德尔的随机化研究
Meijuan Dang1, Ye Li1, Lili Zhao1
1Department of Neurology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Frontiers in public health
|June 14, 2024
概括
暴露于细颗粒物 (PM2.5) 可能因果性地增加阿尔茨海默病 (AD) 的风险. 这项研究使用了门德尔的随机化来将PM2.5暴露与较高的AD发病率联系起来,强调空气质量作为公共卫生问题.
科学领域:
- 环境流行病学环境流行病学
- 神经科学是一个神经科学.
- 遗传流行病学遗传流行病学
背景情况:
- 流行病学研究表明,颗粒物 (PM) 暴露与阿尔茨海默氏病 (AD) 之间存在联系.
- 在PM暴露和AD风险之间建立因果关系是具有挑战性的.
- 门德尔随机化 (MR) 提供了一个强大的方法来调查因果关系.
研究的目的:
- 探索颗粒物暴露与阿尔茨海默氏病 (AD) 风险之间的潜在因果关系.
- 调查PM暴露与其他神经退行性疾病之间的关联.
- 用多变量MR (MVMR) 调整混因子来验证发现.
主要方法:
- 使用全基因组关联研究 (GWAS) 对PM暴露的仪器变量.
- 通过使用五种神经退行性疾病的总结统计数据,对两种样本进行了MR分析.
- 进行敏感性分析和MVMR以确认因果关系并评估稳定性.
主要成果:
- 基因预测的PM2.5暴露与AD风险升高显著相关 (OR2.160,P<0.001).
- 灵敏度分析支持PM2.5-AD关联的稳定性,缓解了质变异的担忧.
- 没有发现PM暴露与其他神经退行性疾病之间的因果关系;MVMR证实了PM2.5-AD关系.
结论:
- 这项MR研究提供了证据,支持PM2.5暴露与阿尔茨海默病之间的因果关系.
- 结果强调了空气质量干预对公共卫生和AD风险降低的重要性.
更多相关视频
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
7.9K
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.9K
相关概念视频
Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462
Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179
